Trajectories of serum α-fetoprotein and intermediate-stage hepatocellular carcinoma outcomes after transarterial chemoembolization: A longitudinal, retrospective, multicentre, cohort study
-
Published:2022-05
Issue:
Volume:47
Page:101391
-
ISSN:2589-5370
-
Container-title:eClinicalMedicine
-
language:en
-
Short-container-title:eClinicalMedicine
Author:
Lu Linbin,
Shen Lujun,
Wu Zhixian,
Shi Yanhong,
Hou Peifeng,
Xue Zengfu,
Lin Cheng,
Chen XiongORCID
Reference37 articles.
1. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Sung;CA Cancer J Clin,2021
2. Metroticket 2.0 model for analysis of competing risks of death after liver transplantation for hepatocellular carcinoma;Mazzaferro;Gastroenterology,2018
3. A novel prognostic index in patients with hepatocellular cancer waiting for liver transplantation: time-radiological-response-alpha-fetoprotein-inflammation (TRAIN) score;Lai;Ann Surg,2016
4. Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial;Zhu;Lancet Oncol,2015
5. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial;Bruix;Lancet,2017
Cited by
13 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献